Comparative Biosciences

Executive Summary

Comparative Biosciences, founded in 1996 and based in Sunnyvale, CA, is a contract research organization (CRO) that operates as a proud member of Genesis Drug Discovery & Development (GD3). The company offers integrated services spanning the entire drug development pipeline, from target discovery through IND filing and management of Phase I–III clinical trials. With nearly three decades of experience, Comparative Biosciences leverages its deep expertise to support biotech and pharmaceutical clients in advancing their preclinical and clinical programs. As a private, pre-clinical stage company, it plays a critical role in the broader drug development ecosystem, providing essential outsourced research services that accelerate timelines and reduce costs for sponsors.

Upcoming Catalysts (preview)

• Q4 2026Securing a major partnership or multi-year contract with a top-20 pharmaceutical company70% success
• TBDExpansion of laboratory facilities or addition of new service capabilities in gene therapy or cell therapy55% success
• Q4 2026Client milestone achievement: First IND clearance from a drug developed with Comparative Biosciences' support80% success